The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier position is being challenged by the IL-17 inhibitors secukinumab (Novartis’s Cosentyx), ixekizumab (Eli Lilly’s Taltz), and brodalumab (Bausch Health’s Siliq, Leo Pharma’s Kyntheum, Kyowa Hakko Kirin’s Lumicef) and by the IL-12/23 inhibitor ustekinumab (Janssen’s Stelara). With the approvals of the IL-23 inhibitors guselkumab (Janssen’s Tremfya), tildrakizumab (Merck & Co. / Almirall / Sun Pharma’s Ilumya / Ilumetri), and, more recently, risankizumab (AbbVie / Boehringer Ingleheim’s Skyrizi), another effective drug class has been introduced to this increasingly competitive market. The landscape for the established biologics will change even further with the increasing availability and use of biosimilars.
- How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors Cosentyx, Taltz, and Siliq / Kyntheum / Lumicef and the emerging IL-17 A/F dual inhibitor UCB’s bimekizumab, and where are / will these agents be positioned in the psoriasis treatment algorithm?
- What will be the impact of the IL-23 inhibitors Tremfya, Ilumya, Skyrizi, and mirikizumab (emerging from Eli Lilly), and how will they fare in the competitive psoriasis market?
- How is the oral agent apremilast (Amgen’s Otezla) used for psoriasis, and how will it be compared with the emerging oral TYK2 inhibitor BMS-986165?
- How fast will the uptake of biosimilars occur in psoriasis, and which brands will suffer the most erosion in patient share and sales?
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 18 country-specific interviews with thought leaders. Supported by survey data collected for this and other DRG research.
Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.
Emerging therapies: Phase III/PR: 5 drugs; Phase II: 11 drugs; coverage of select preclinical and Phase I products.
Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2028, segmented by brands/generics and epidemiological subpopulations.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Psoriasis - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Mohit Nasa, MBA; T.J. Arndt, MPH, CPH
Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis.
He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.
T.J. joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia.
T.J. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a B.S. in Microbiology & Cell Science and a B.A. in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.